Category Neurology

BARCELONA — In a first-in-human clinical trial, an investigational messenger RNA (mRNA)-based cancer vaccine for glioblastoma induced tumor-associated antigen-specific T-cell responses in more than three quarters of patients and had an acceptable safety profile.  “These early data are encouraging,” Ghazaleh…